Our latest thinking, insights and company news

Never miss an update, subscribe today.

RJW&partners will only use your personal information to administer your account and provide the products and services you request. You can unsubscribe at any time, to do so please review our Privacy Policy. By clicking subscribe, you consent to allow RJW&partners to store and process your personal information.

Jun 28, 2021
4 min

The management of orphan drug prices after loss of exclusivity

What happens to orphan drugs when they lose market exclusivity? Do they face generic competition and price reductions like other drugs?...

427 views

Jun 8, 2021
4 min

Biden and big change: is he just getting started?

Biden has unveiled his proposed 2022 budget, which reveals his healthcare policy priorities but lacks financial details.

41 views

Jun 2, 2021
5 min

Biosimilar uptake: will the US catch up with Europe?

Uptake of biosimilars has been much slower in the US compared to Europe. Could recent and upcoming reforms change this?

74 views

Mar 31, 2021
4 min

Back to the future: Covid-19 has increased the appetite for centralisation of decision-making

NHS England is set to achieve its commitment to roll out Integrated Care System (ICSs) across England by April 2022.

136 views

Mar 22, 2021
3 min

Germany mandates real-world data collection for gene therapy Zolgensma

Germany’s HTA body is telling Novartis exactly what post-approval efficacy data it needs to see for SMA therapy Zolgensma.

470 views

Mar 8, 2021
3 min

Could Germany’s free-pricing period be cut in half?

Drug-makers currently enjoy a year of free pricing in Germany, before the impact of an added-benefit assessment kicks in. According to Josef